abstract |
A fusion protein to which an anti-c-Met antibody and a VEGF binding fragment are linked, a dual target antibody comprising the fusion protein, a polynucleotide encoding the fusion protein, a transformant comprising the polynucleotide, and the double target antibody are effective. A pharmaceutical composition comprising as a component, and a method for producing a dual target antibody simultaneously targeting c-Met and VEGF with improved anti-cancer and neovascular suppression efficacy, comprising linking a VEGF binding fragment to an anti-c-Met antibody. This is provided. |